Simponi Aria (golimumab) for Intravenous Use
Customize your policy alerts
Sign up for Bluecross Idaho Policy MP 5.01.670 alerts
Get alerted when Policy MP 5.01.670 changes without checking for updates manually.
Monitor payer policy activity
Medical-benefit coverage and prior authorization for intravenous golimumab for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. Subcutaneous golimumab is handled under the pharmacy benefit and is outside this policy.
Covered indications now include rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis when medical criteria are met.
The policy added a statement regarding indications in the NCCN Drugs & Biologics Compendium.
The policy clarified criteria related to tuberculosis infections and tuberculosis screening.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.